UPDATE 1-Onyx says FDA agrees on blood cancer drug trial design

* Reaches agreement with FDA on Special Protocol Assessment

* Sees carfilzomib combination trial beginning in H1 2010

Feb 2 (BestGrowthStock) – Onyx Pharmaceuticals Inc (ONXX.O: ) said it
reached an agreement with the U.S. Food and Drug Administration
on the design of the late-stage trial of its blood cancer drug.

The company said the trial was designed to evaluate the
efficacy of its drug, carfilzomib, in combination with certain
other compounds.

The trial, expected to begin in the first half of 2010,
will enroll patients with relapsed multiple myeloma, Onyx said.

Onyx acquired carfilzomib with its purchase of Proteolix
Inc.

Shares of the biopharmaceutical company closed at $28.62
Monday on Nasdaq.

Growth Stocks

(Reporting by Anuradha Ramanathan in Bangalore; Editing by
Vinu Pilakkott)

UPDATE 1-Onyx says FDA agrees on blood cancer drug trial design